glp1ledger

What a GLP-1 Costs Through Ro, Read From the Manufacturers' Own Releases

Ro does not discount the drug. Novo's and Lilly's releases show Ro charges the manufacturers' own prices, and the subscription ladder that reaches $249 a month is prepaid. Read 2026-09-19.

Ronald R · Edited by Caroline S · Published 2026-09-19

Illustration: An open white box and an empty glass of water on a wooden surface in natural light.
Illustration

Ro is the largest telehealth route into a GLP-1 that we had not yet priced, and pricing it has been awkward for one specific reason: Ro's own website serves an automated-traffic challenge to our requests, and this site does not work around those. So this page is built from a different set of documents, and the set turns out to be better than the website would have been.

Ro issues its press releases through a wire service. Novo Nordisk and Eli Lilly issue theirs through the same one, and both name Ro. Between them those releases carry every price on this page, dated, quoted and attributable — and they establish the one thing that matters most about buying a GLP-1 through Ro, which is that Ro does not set the price of the drug.

What the drug costs

Every figure below is the manufacturer's, taken from the manufacturer's or Ro's own release. Read 2026-09-19.

Zepbound, through Lilly's direct channel

Dose Monthly price Condition
2.5 mg $299 Starting dose
5 mg $399 —
7.5, 10, 12.5, 15 mg $449 Only when the refill is completed within 45 days of the previous delivery

Ro's release of 2026-04-02 announces the Zepbound KwikPen on its platform at those prices. Lilly's own release of 2026-02-23, announcing the KwikPen label expansion, states that patients with a valid prescription "opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or single dose vial, starting at $299 per month for the 2.5 mg dose."

Those are the same numbers. Ro is not discounting Zepbound; it is reselling Lilly's self-pay price. The 45-day refill condition on the higher doses is Lilly's condition too, and it is the same one our Zepbound cost page documents: a purchase offer that lapses if a refill runs late, not a standing price.

Wegovy, through Novo's subscription programme

Novo Nordisk announced a multi-month subscription programme on 2026-03-31, available "through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and others to follow soon." The prices are Novo's:

Product 3-month 6-month 12-month Standing self-pay
Wegovy pen (0.25–2.4 mg) $329/mo $299/mo $249/mo $349/mo
Wegovy pill (9 mg, 25 mg) $289/mo $269/mo $249/mo $299/mo

Wegovy HD at 7.2 mg is to be added later; the pill's 1.5 mg and 4 mg doses stay at their separate $149 offer pricing.

Two things in that table are not in either company's release, and both come out of subtracting its own numbers.

The pen and the pill converge at $249. On a twelve-month subscription the dosage form stops affecting the bill entirely. At every shorter commitment, and at the standing self-pay price, the pill is $50 cheaper. Anyone choosing between an injection and a tablet on cost grounds is choosing on cost grounds only if they are not prepaying a year.

The advertised savings are measured against Novo's own retail price, not against list. $349 − $249 = $100 a month, which is the "$1,200/year" the release claims. $299 − $249 = $50, which is its "$600/year" for the pill. Both are true. Neither is a comparison with the $1,349.02 list price recorded on our cost page, and neither is a discount Ro is funding.

The part the releases do not put in the headline

Ro's release describes the options as "3, 6 and 12 month prepaid plans."

So the cheapest monthly figure is the one attached to the largest single payment. Twelve months at $249 is about $2,988 committed in advance, for a drug whose discontinuation rate is the central fact of the category. The two randomised trials that withdrew these drugs under blind conditions found the average participant had regained 14.8% of body weight a year later — which is an argument for staying on treatment, and also a reason to read what a prepaid year says about unused months.

We could not read those terms. Ro's own pricing and terms pages serve an automated-traffic challenge to our requests, and we do not defeat those. That is the honest state of it: the drug prices here are fully documented from manufacturer sources, and the cancellation and refund terms of the prepaid plans are not documented at all. Anyone considering the twelve-month rate should ask Ro directly what happens to unused months, and get the answer in writing before paying.

What Ro itself charges

Ro's own charge is the Body membership, and this is the second gap.

The only membership figures in Ro's releases are historical. In May 2025 it announced a discounted first month of $45, which combined with Novo's $199 first-month Wegovy offer to produce a first month of $244 for care and medicine together. In March 2026 it said new, lower-priced membership options were arriving "in April," without naming a price.

We are not going to quote a current figure we have not read. The membership price is the entirety of what Ro adds to the manufacturer's price, so it is also the single most important number for anyone comparing routes — and it is the one number a reader has to get from Ro.

What the membership contains is documented, from Ro's own releases: access to a licensed provider, 24/7 messaging, one-to-one coaching, educational content, weight tracking and dose logging, labs where appropriate, side-effect monitoring, and monthly check-ins covering dose titration and counselling. Ro also operates a free GLP-1 insurance checker which its March 2026 release says more than two million people have used.

That is a fuller service than a prescription and a delivery, and it may well be worth paying for. It is simply not a cheaper drug.

The price history, from three Novo documents

One of the advantages of building this from dated releases is that the series is legible. Every figure is Novo's own, for the same Wegovy pen:

Date Price Source
March–April 2025 $499/month Novo's release of 2025-04-29 opening NovoCare Pharmacy to Ro, Hims & Hers and LifeMD
2026-09-19 $349/month standing self-pay NovoCare pricing page
2026-09-19 $249/month on a 12-month prepay Novo's subscription release of 2026-03-31

A 30% fall in the standing price in eighteen months, and 50% at the prepaid rate. Nothing about the medicine changed; the market did.

A second piece of drift in the same series is worth recording because it is the kind of thing that makes an undated price worse than no price. Novo's press release of 2026-04-07 described the $199 two-fill starter offer as running "through June 30, 2026." The NovoCare pricing page read on 2026-09-19 describes the same offer as running "through December 31, 2026." The introductory price has been extended at least once, by at least six months, with no announcement we could find. Which is exactly why every figure on this site carries the date it was read.

The thing that is genuinely different about Ro

In April 2025 Novo Nordisk named three telehealth companies as direct routes into NovoCare Pharmacy: Hims & Hers, LifeMD and Ro. In June 2025 it issued a press release terminating one of them by name, stating that the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization'."

We found no comparable Novo statement about Ro, and Ro appears in Novo's March 2026 subscription release as a launch partner. Ro's own release notes it connected to Lilly's direct-to-patient channel in December 2024 and to Novo's in April 2025, making it the earliest and the continuous one of the group.

That is a fact about the stability of a supply route, and it is worth something to anyone planning a year of treatment. It is not a judgement about clinical quality, which a press release cannot supply. The other side of that story — what happened to the terminated company, and where it stands now — is on what a GLP-1 costs through Hers.

What we could not verify, stated plainly

This site's methodology says that where a repeated figure has no findable source we say so. Four things on this page are gaps rather than findings:

  1. The current Body membership price. Not in any release; site not readable.
  2. Cancellation and refund terms on the prepaid subscriptions. Same reason.
  3. Whether Ro's catalogue includes any compounded GLP-1. Every product named in its releases is FDA-approved, but a release is not a catalogue.
  4. Ro's Foundayo pricing. Ro announced in 2026 that it offers Foundayo; no price for it appears in the release we opened, and Lilly's published self-pay figure for the lowest dose is from $149.

Everything else here is a manufacturer's own dated figure.

The comparison that matters

Because the drug price is the manufacturer's either way, the only question a cost comparison can answer is what the membership buys. The other telehealth routes we have priced split that differently: WeightWatchers charges $74 a month and excludes the medication entirely, Noom's advertised $79 sits above a $199 continuing figure, Costco's member benefit contains no GLP-1 line at all, and the fullest view of a large operator's weight-loss economics comes from Hims & Hers' SEC filings rather than its price page. The manufacturer-by-manufacturer picture is on the GLP-1 cost page.

Sources

All read 2026-09-19.

Frequently asked questions

How much does a GLP-1 cost through Ro?

The drug costs what the manufacturer charges, and that is the point most comparisons miss. From the manufacturers' own releases, read 2026-09-19: the Zepbound KwikPen starts at $299 a month for 2.5 mg and $399 for 5 mg, with 7.5 mg and above at $449 when a refill is completed within 45 days of the previous delivery. Wegovy is $349 a month standing self-pay for most pen doses, or $329, $299 and $249 on 3, 6 and 12-month prepaid subscriptions; the Wegovy pill's maintenance doses are $289, $269 and $249 on the same ladder. On top of the drug sits Ro's Body membership, whose current price is not stated in any release we could open.

Is Ro cheaper than buying direct from the manufacturer?

For the medicine, no, and both manufacturers say so in their own words. Lilly's release of 2026-02-23 puts self-pay Zepbound through LillyDirect at $299 a month for the 2.5 mg dose - the same figure Ro quotes. Novo's subscription programme is a Novo programme offered through several telehealth companies at the same prices. Ro's claim is convenience and clinical service, not a lower drug price, and the arithmetic to do is the membership fee against the value of the service, because the medicine costs the same either way.

What is the catch with the $249 Wegovy price?

It is prepaid. Ro describes the 3, 6 and 12-month options as prepaid plans, so the lowest monthly figure is also the one that requires the largest single payment - roughly $2,988 for twelve months at $249. That is a reasonable trade for someone certain they will stay on treatment, and a poor one for someone who may not. The relevant evidence is not encouraging about certainty: the two randomised trials that withdrew these drugs under blind conditions found the average participant regained 14.8% of body weight within a year, which is covered on our page about stopping a GLP-1. Before committing twelve months, the questions worth asking are what happens to unused months and whether the plan can be cancelled - terms we could not read, because Ro's own site blocks automated requests.

How much is Ro's Body membership?

We will not quote a figure, because no current one appears in any document we could open on 2026-09-19. What the record holds is historical: in May 2025 Ro offered a discounted first month of $45 for the Body membership, which combined with Novo's $199 first-month Wegovy offer to make a $244 first month; and in March 2026 Ro said new lower-priced membership options were arriving 'in April' without naming them. Ro's own pricing page serves an automated-traffic challenge to our requests, and this site does not work around those, so the membership price is a gap here rather than an estimate. It is also the whole of Ro's own charge, so it is the number to get from Ro directly before signing up.

What does the Body membership actually include?

From Ro's own releases: access to a licensed provider, 24/7 messaging, one-to-one coaching, educational content, weight tracking and dose logging, labs when appropriate, side-effect monitoring, and monthly check-ins covering dose titration and counselling. Ro also runs a free GLP-1 Insurance Checker, which its March 2026 release says has been used by over two million people. That is a fuller service than a prescription-only route, and whether it is worth its price is the only real question on this page, because the medicine is priced by the manufacturer.

Does Ro sell compounded semaglutide?

Nothing in the releases we read describes Ro selling compounded GLP-1s in 2026; every product named in them is an FDA-approved one - Wegovy pen, Wegovy pill, Zepbound KwikPen and Foundayo - sold through the manufacturers' own direct channels. That is a meaningful distinction in this market, because the compounded route is where the regulatory action has been. It also cannot be confirmed from a press release alone: a release describes what a company announces, not its whole catalogue, and Ro's own site did not serve our requests.

Why is Ro still selling Wegovy when Novo dropped other telehealth companies?

Novo named three telehealth companies in April 2025 when it opened NovoCare Pharmacy to them - Hims & Hers, LifeMD and Ro. In June 2025 it publicly terminated one of them by name and by reason. Ro has not been the subject of any such Novo statement we could find, and it appears in Novo's March 2026 subscription release as a launch partner. On the public record Ro is the continuous one of the three, which is a fact about supply reliability rather than a judgement about care quality.

Which is cheaper through Ro, Wegovy or Zepbound?

It depends entirely on the dose and the commitment, and there is a crossover. At the starting dose Zepbound's KwikPen at $299 undercuts Wegovy's standing $349. At maintenance, Zepbound's higher doses are $449 with a 45-day refill condition attached, while a 12-month Wegovy subscription is $249 with no such condition but with the full year prepaid. So the cheaper drug at the start is the more expensive one at maintenance, and the comparison flips depending on whether a year can be paid for in advance. Neither figure is a Ro price; both are manufacturer prices.